Vimarsana
Biggest News Aggregation in the World

Currently Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Currently Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Currently Expected Today - Breaking & Trending Today

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC) - Vimarsana News

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

Published: May 10, 2023

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled... | May 10, 2023

Source: marketscreener.com
Related Topics:
United StatesSacituzumab GovitecanSacituzumab Govitecan HziyRaj MalikInvestor Relations Corporate CommunicationsEuropean Society For Medical OncologyResearch Triangle ParkExchange CommissionTherapeutics IncAmerican Cancer SocietyTarget EffectTrilaciclib Reduces RatesMultiple Adverse Events AssociatedIncluding NeutropeniaEnrolled Patients Received PriorInitial Objective Response RateOverall Study Population ConsistentCheckpoint Inhibitor Pretreated PopulationTumors RelativeOverall Study PopulationExpectation BasedEnhance Anti Tumor ImmunityCurrently ExpectedFirst QuarterChief Medical Officer
New Results from Phase 2 Trial Confirm Benefit of - Vimarsana News

New Results from Phase 2 Trial Confirm Benefit of

Published: May 10, 2023

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia,...

Source: globenewswire.com
Related Topics:
United StatesSacituzumab GovitecanRaj MalikSacituzumab Govitecan HziyEuropean Society For Medical OncologyAmerican Cancer SocietyResearch Triangle ParkTherapeutics IncInvestor Relations Corporate CommunicationsExchange CommissionTarget EffectTrilaciclib Reduces RatesMultiple Adverse Events AssociatedIncluding NeutropeniaEnrolled Patients Received PriorInitial Objective Response RateOverall Study Population ConsistentCheckpoint Inhibitor Pretreated PopulationTumors RelativeOverall Study PopulationExpectation BasedEnhance Anti Tumor ImmunityCurrently ExpectedFirst QuarterChief Medical Officer
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update - Vimarsana News

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Published: November 14, 2022

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...

Source: prnewswire.com
Related Topics:
United StatesCarl SpanaPalatin Technologies IncPrnewswire Palatin Technologies IncSecurities ExchangeDry Eye Disease OngoingInterim AnalysisStudy SizeProduct Revenue IncreasedPrescriptions Dispensed IncreasedRefills ExceedTotal PrescriptionsUlcerative Colitis CommencedInterim Analysis First Quarter CalendarCurrently ExpectedThird Quarter CalendarRegistered DirectFiscal First Quarter Ended SeptemberHypoactive Sexual Desire DisorderDirect OfferingCommon WarrantPre Funded WarrantCommon WarrantsPre Funded WarrantsStock Split